… with the PE in the RE-COVER/RE-COVER II studies. We, … pooled analysis of the RE-COVER/RE-COVER
II studies, which corresponds with 2.9% for patients treated with dabigatran…

… of life (HRQoL) after acute DVT and pulmonary embolism (PE) … The RE‐COVER and
RE‐COVER II studies randomized … of treatment with either dabigatran (150 mg BID) or warfarin …

… in patients with deep vein thrombosis and/or pulmonary embolism (DVT/PE). The objective
… study than those reported in a pooled analysis of the RE-COVER and RE-COVER II …

… (New York Heart Association classes II–IV), and pooled 6-minute walk distance … apixaban
and rivaroxaban, respectively. The RE-COVER II trial confirmed the findings of the RE-COVER …

… phase of parenteral heparin anticoagulation for 7–10 days; two further DOACs, apixaban and
rivaroxaban, were also tested as part of a … with dabigatran or warfarin and pooled analysis. …

… In the RE-COVER and RE-COVER II studies, dabigatran was administered at a fixed dose
of 150 mg twice daily after a lead-in treatment with parenteral unfractionated heparin, LMWH, …

… pulmonary embolism or if pulmonary embolism could not be ruled out. … dabigatran versus
warfarin for the treatment of acute venous thromboembolism: a pooled analysis from re‐cover …

… thrombosis (DVT) and pulmonary embolism (PE) and is a … III clinical trials of RE-COVER
and RE-COVER II. These trials included … Data from these two randomized trials were pooled to …

… treatments; those patients are hemodynamically unstable with acute pulmonary embolism,
and … A landmark subanalysis of the Amplify study assessed the efficacy and safety of apixaban …

… The anticoagulant for completely oral treatment was apixaban in 38.0% and rivaroxaban in
… regimens with DOACs, the duration of parenteral therapy was two to seven days in 1288 (77.1…